Vancomycin dry powder inhalation - Savara Pharmaceuticals

Drug Profile

Vancomycin dry powder inhalation - Savara Pharmaceuticals

Alternative Names: AeroVanc; Vancomycin hydrochloride inhalation powder

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Savara Pharmaceuticals
  • Class Antibacterials; Glycopeptides; Peptide antibiotics
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Methicillin-resistant Staphylococcus aureus infections
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Bronchiectasis; Methicillin-resistant Staphylococcus aureus infections; Nosocomial pneumonia
  • New Molecular Entity No
  • Available For Licensing Yes - Methicillin-resistant Staphylococcus aureus infections

Highest Development Phases

  • Phase II Methicillin-resistant Staphylococcus aureus infections
  • Phase I Bronchiectasis
  • Preclinical Nosocomial pneumonia

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Methicillin-resistant-Staphylococcus-aureus-infections in Australia (Inhalation, Powder)
  • 01 Mar 2016 Savara Pharmaceuticals plans a phase III trial for Methicillin-resistant Staphylococcus aureus infections in USA and Canada
  • 23 Feb 2015 Adverse events data from the phase II trial in Methicillin-resistant Staphylococcus aureus infections released by Savara Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top